Highlights

  • Cochlear (ASX:COH) has declared a $1.30 per share final dividend, franked to 85%.
  • The Dividend has an ex-dividend date of 21 September 2026 and payment date of 14 October 2026.
  • The final dividend carries an annual Yield of 2.53%.
  • Cochlear remains a global hearing-implant leader, with Recurring Revenue from its growing installed base.

Cochlear (ASX:COH), the global leader in implantable hearing devices and one of Australia's premier healthcare exporters, has declared a final dividend of $1.30 per share. The payment is franked to 85%, with an ex-dividend date of 21 September 2026, a Record Date of 22 September 2026 and payment due on 14 October 2026. The dividend carries an annual yield of 2.53%. The final is notably lower than the $2.15 paid a year earlier, taking Cochlear's full-year FY26 distribution to about $3.45 per share, down from $4.30 in FY25. For a company long prized more for growth than yield, the reduced final is a talking point, even as Cochlear remains a world-class Franchise with a dominant position in its market.

Cochlear's $1.30 final is franked to 85%, grossing up to roughly $1.77 including franking credits. Investors entitled to the dividend based on the relevant record date will be paid on 14 October. It is a step down from the $2.15 final of a year earlier, and follows an interim of $2.15 paid in April, leaving the full-year FY26 payout at about $3.45 versus $4.30 the prior year.

Cochlear targets a payout of around 70% of underlying net profit, so a smaller final points to softer full-year Earnings relative to FY25. Note too that Cochlear is no longer a fully franked payer: franking has stepped down in recent years — from as low as 35% in 2023 toward 85% now — reflecting the large share of profit earned overseas. Investors valuing franking should Factor in that 15% of this dividend carries no credits.

What is driving the business?

Cochlear designs, manufactures and sells cochlear implants, bone-conduction devices and acoustic implants, along with the sound processors and services that support them. It commands a leading global share of the hearing-implant market and sells into more than 100 countries, giving it genuine international scale and a long runway as awareness and access to hearing solutions expand.

A key strength is Cochlear's growing base of implant recipients, who periodically upgrade their sound processors — a recurring, higher-margin services stream that complements new implant sales. The company invests heavily in Research and Development to defend its technology lead. Earnings can nonetheless vary with new-product cycles, foreign-exchange movements, surgery volumes and growth investment, all of which feed into the profit that drives the dividend.

Why income investors may be watching

Cochlear has rarely been bought for income — its appeal has been long-term structural growth — but it does pay a substantial, partly Franked Dividend backed by a highly profitable, cash-generative business. For shareholders, the payout is a reliable, if modest-yielding, complement to the growth story.

The reduction in the final will draw attention to the direction of earnings, since the dividend follows profit under the payout policy. Investors may want to watch how FY26 results and management's outlook frame the trajectory, and whether the softer final is a one-off or a signal of a more cautious near-term profit picture.

Risks

Cochlear trades on a premium, growth-oriented valuation, leaving the shares sensitive to any disappointment in earnings or guidance. A lower final dividend underscores that profits — and therefore distributions — can move with product cycles, currency and Investment spending.

The company faces competition in hearing implants, regulatory and reimbursement risks across many markets, and exposure to elective-surgery volumes. Its heavy offshore earnings bring currency risk and dilute franking. Dividends are tied to profit under a payout policy, so they can fall as well as rise, as this year illustrates.

Investor takeaway

Cochlear's $1.30 final dividend, franked to 85%, is lower than a year ago and takes the full-year payout down to about $3.45 from $4.30, reflecting the company's policy of paying out a set proportion of underlying profit. The Business remains a dominant global healthcare franchise with a valuable recurring services stream, but income is secondary to its growth appeal, the dividend is only partly franked, and the softer final points to earnings worth scrutinising. Investors may want to watch the FY26 result and outlook closely.